Page 45 - NobleCon21

Aytu BioPharma, Inc.

SELECTED FINANCIAL ITEMS AYTU
(in millions of USD)
CQ4 '24 CQ1 '25 CQ2 '25 CQ3 '25 LTM
Income Statement Key Items
Total Revenue 16.22 18.45 15.14 13.89 63.70
Gross Profit 10.79 12.81 10.25 9.19 43.03
Gross Margin 66% 69% 68% 66% 68%
EBIT (0.38) 2.42 0.64 (1.50) 1.18
EBIT Margin -2% 13% 4% -11% 2%
Net Income to Common Shareholders 0.79 3.99 (19.82) 1.97 (13.07)
Net Margin 5% 22% -131% 14% -21%

Balance Sheet Key Items
Total Assets 116.23 124.20 124.18 124.99 124.99
Cash & Short Term Investments 20.40 18.17 30.95 32.63 32.63
% of Assets 18% 15% 25% 26% 26%
Current Assets -Total 63.05 72.51 79.18 81.11 81.11
% of Assets 54% 58% 64% 65% 65%
Total Liabilities 85.46 89.30 105.21 101.82 101.82
% of Assets 74% 72% 85% 81% 81%
Current Liabilities - Total 64.05 70.71 63.06 65.99 65.99
% of Assets 55% 57% 51% 53% 53%
Long Term Debt 9.98 9.54 10.90 10.45 10.45
% of Assets 9% 8% 9% 8% 8%
Total Equity 30.77 34.90 18.97 23.17 23.17
% of Assets 26% 28% 15% 19% 19%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities 2.91 (6.46) 2.80 (0.62) (1.37)
Net Cash Flow - Investing 0.15 (0.07) (3.02) NA (2.94)
Net Cash Flow - Financing (2.76) 4.30 12.99 2.30 16.83

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference